Treating Together

Targeted Oncology

Targeted Oncology brings you Treating Together, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

  1. Navigating the Future of CLL Care

    VOR 1 TAG

    Navigating the Future of CLL Care

    In this episode of Treating Together, host Marc Braunstein, MD, an associate professor of medicine at the Perlmutter Cancer Center, NYU Grossman School of Medicine, is joined by John Burke, MD, from Rocky Mountain Cancer Centers. Both specialists bring their extensive experience in lymphoma and multiple myeloma to a deep-dive discussion on the rapidly evolving treatment landscape of chronic lymphocytic leukemia (CLL). Key Discussion PointsThe episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on whether patients benefit more from indefinite BTK inhibitor use or time-limited regimens. The role of MRD: Exploring how minimal residual disease (MRD) driven duration is becoming a sophisticated option for tailoring treatment. Clinical trial updates: Analysis of recent data regarding frontline treatment outcomes and infectious risks. Relapsed/refractory strategies: Insights into the recent FDA approval of pirtobrutinib (Jaypirca) for second-line therapy and beyond. Looking Toward the FutureAs the experts look ahead into 2026, they discuss the promising emergence of BTK degraders, which have shown high response rates in heavily pretreated patients and are moving toward potential market availability in the coming years.

    17 Min.
  2. Supporting Community Oncologists in a GU Research Era with Dr. Park, Dr. Garmezy, and Dr. Bupathi

    21. JAN.

    Supporting Community Oncologists in a GU Research Era with Dr. Park, Dr. Garmezy, and Dr. Bupathi

    This episode of Treating Together, hosted by Chandler Park, MD, featuring guests Benjamin Garmezy, MD, and Manoj Bupathi, MD,  centers on the intersection of clinical research and community oncology, specifically within the field of genitourinary (GU) oncology. Core Themes and Discussion Points The Community Oncology Gap: Park highlights a critical statistic: 80% to 85% of patients with cancer are treated in community settings rather than academic centers. The podcast aims to support these community clinicians by translating complex data into practical applications. Rapidly Evolving Data: The group discusses the immense challenge of staying current with novel biomarkers, immunotherapy, targeted therapies, and AI in pathology. The Burden on Generalists: Garmezy notes that while specialists find it hard to keep up, the "real heroes" are the general community oncologists who see a wide variety of conditions and may only see a handful of GU-specific cases per year. Bridging the Research Divide: A primary goal is to narrow the gap between clinical trial findings and real-world clinical practice, ensuring that patients in the community benefit from the latest research. Find a full transcript of the podcast at https://www.targetedonc.com/view/supporting-community-oncologists-in-a-gu-research-era

    27 Min.
  3. Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD

    15.12.2025 · BONUS

    Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD

    Treating Together

    7 Min.
  4. Experts Delve Into Organ Preservation for Genitourinary Cancers

    31.10.2025

    Experts Delve Into Organ Preservation for Genitourinary Cancers

    Benjamin Garmezy, MD, and Alexander Kenigsberg, MD, discuss strategies for preserving organs in GU cancers in the Treating Together podcast.

    26 Min.
  5. Navigating Modern Lung Cancer Treatment and Clinical Trial Access

    29.09.2025

    Navigating Modern Lung Cancer Treatment and Clinical Trial Access

    Edward S. Kim, MD, MBA, and Neel Shah, MD, discuss advancing lung cancer care and tackling real-world access barriers for community physicians.

    23 Min.
  6. Advancing Prostate Cancer Treatment With Shared Decision-Making

    31.07.2025

    Advancing Prostate Cancer Treatment With Shared Decision-Making

    In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.

    25 Min.
  7. Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

    15.04.2025

    Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

    In this episode of Emerging Experts, Xiaojie Zhang, MD, a hematology/oncology fellow, and Akshat Singhal, PhD, a postdoctoral scholar, both at UC San Diego, shed light on innovative research leveraging deep learning to predict how patients with ER-positive/HER2-negative (ER+/HER2-) breast cancer will respond to palbociclib (Ibrance), a common first-line treatment for this patient population. Their work, fueled by the desire to improve precision oncology, demonstrates the significant potential of artificial intelligence (AI) in guiding cancer care.

    37 Min.
  8. BMT CTN 1902 in Myeloma: Key Findings With Garfall

    13.03.2025

    BMT CTN 1902 in Myeloma: Key Findings With Garfall

    In this episode of Targeted Talks, Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial (NCT05032820) of idecabtagene vicleucel (ide-cel; Abecma), a study focused on patients with multiple myeloma who had a suboptimal response to first-line therapy, including autologous hematopoietic cell transplant and lenalidomide (Revlimid) maintenance.

    15 Min.
Alle anzeigen (77)

Info

Targeted Oncology brings you Treating Together, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

Informationen

  • Erstellt von
    Targeted Oncology
  • Jahre aktiv
    2020 - 2026
  • Folgen
    77
  • Bewertung
    Unbedenklich
  • Copyright
    © MJH LifeSciences
  • Sendungswebsite
    Treating Together